UNVEILpharma
innovation. unveiled.
Creating new opportunities in Biotech
How
World-class deal flow
From Harvard, MIT, Wyss ...
IND to Phase II
Sharp focus on curated technologies with an exit horizon of 5 years max.
Operational Value Add
Deep sector expertise in drug development and commercialization
Initial target indications
If you would like to receive our updates or more information, please let us know:
UNVEILpharma.
BOSTON
SINGAPORE
CC0 CopyLeft UNVEILpharma